Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Non-Small-Cell Lung Cancer
DRUG: Vebreltinib|DRUG: Osimertinib|DRUG: PLB1004
The objective response rate of the tumor (ORR), The incidence of confirmed complete response or partial response., 2 Years
The disease control rate (DCR), The incidence of complete response, partial response and stable disease., 2 Years|Duration of Response (DoR), The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded., 2 Years|Progression-free survival (PFS), Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)., 2 Years|Time to Response (TTR), The period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail)., 2 Years|Incidence of Treatment-Emergent Adverse Events, Incidence of Treatment-Emergent Adverse Events (TEAEs),A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug., 2 Years
A Multicenter,Randomized,open-label,Phase II Study to Evaluate the Efficacy and Safety of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients with EGFRm+(exon 19 deletion or exon 21 L858R)/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer.